Glimepiride

Mechanism

Pharmacological Class and Group

Third generation sulfonylurea (oral insulin secretagogue).

Mechanism of Action

Physiological insulin secretion is coupled to intracellular glucose metabolism. Glucose metabolism raises intracellular ATP, closing ATP-sensitive potassium (K_ATP) channels in the pancreatic beta cell membrane.

Cellular and Ion Channel Mechanism

1. Binding to the SUR1 receptor: Glimepiride selectively binds to a 65 kDa molecular weight regulatory subunit of the sulfonylurea receptor 1 (SUR1), which is structurally coupled to the central pore of the ATP-dependent potassium channel (K_ATP, Kir6.2) in the pancreatic beta cell.

2. Closure of the K_ATP Channel: Molecular coupling blocks the cellular potassium efflux current:

Blocking of the K_{ATP channel} Intracellular accumulation of K⁺ Membrane depolarization (-70 mV → -30 mV)

3. Opening of L-Type Calcium Channels: Membrane depolarization opens voltage-gated calcium channels, inducing a massive influx of extracellular calcium.

4. Exocytosis of Insulin Granules: The increase in free cytosolic calcium triggers the exocytosis of preformed insulin vesicles. This effect is independent of extracellular glucose levels, which explains the inherent ability to induce profound hypoglycemia.

Pharmacokinetics

High Resolution Pharmacokinetics

• Absorption and Bioavailability: Complete bioavailability (100%) after oral administration. Food intake slightly delays T_max (reached 2.5 hours post-ingestion).
• Distribution: Very small volume of distribution (8.8 L). Extreme binding to plasma proteins (99.5%), mainly to albumin, which predisposes to displacement interactions.
• Metabolism: Extensive phase I hepatic metabolism mediated selectively by cytochrome CYP2C9. It is transformed to its main metabolite, the cyclohexylhydroxymethyl derivative (M1), which has 30% of the biological activity of the original molecule, and subsequently to its inactive carboxyl derivative (M2) by tissue dehydrogenase.
• Excretion: Elimination of 60% through the kidneys (mainly as metabolites M1 and M2) and 40% through feces and bile.
• Half-life (t_1/2): Elimination half-life of 5 to 8 hours, significantly prolonged in the elderly or in kidney disease.

Indicators and dose

Clinical Indications and Off-Label Uses

• Type 2 Diabetes Mellitus: For glycemic control when dietary measures and metformin are insufficient or are not tolerated. Its use has decreased significantly due to the arrival of cardiorenoprotective drugs (SGLT2i, arGLP-1).

Dosage and Clinical Adjustment

Scheme in Adults:

• Initial Dose: 1 mg once daily orally, administered with breakfast or the first main meal.
• Titration: Increase at a rate of 1 mg every 1-2 weeks according to capillary glycemic controls.
• Usual Maintenance Dose: 1 mg to 4 mg per day.
• Maximum Approved Dose: 6 mg once a day (exceptionally 8 mg/day, but without measurable added clinical benefit).

Adjustment in Renal Failure: Start with 1 mg per day. If the eGFR is < 30 mL/min/1.73 m², the use of the drug is strongly discouraged due to cumulative risk. Avoid on dialysis.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Diabetes Mellitus Type 1 or diabetic ketoacidosis.
• Hypersensitivity to glimepiride or other sulfonylureas / sulfonamides (cross-reactions).
• Severe liver failure or advanced decompensated cirrhosis.
• eGFR < 15 mL/min/1.73 m² (high risk of active M1 accumulation).

Relative Contraindications

• Elderly, malnourished or weakened patients (high risk of irreversible brain damage due to hypoglycemia).
• Genetic glucose-6-phosphate dehydrogenase (G6PD) deficiency (increased risk of hemolytic anemia).

Adverse Effects (ADR) and Specific Toxicity

• Frequent (1%-10%): Hypoglycemia (it is the most dangerous ADR, it can last for a long time and require hospitalization), weight gain (due to the anabolic effect of the insulin released), dyspepsia, nausea, headaches.
• Uncommon (0.1%-1%): Transient visual disturbances at the beginning of treatment (due to osmotic changes of the lens), pruritus, erythematous skin rashes.
• Rare (0.01%-0.1%): Moderate to severe thrombocytopenia, leukopenia, hemolytic anemia, cholestatic jaundice due to intrahepatic cholestasis.

Critical Toxicity: Hypoglycemia Sustained by Sulfonylureas

Hypoglycemia due to sulfonylureas can be prolonged (greater than 24-48 hours) due to the accumulation of metabolites with active biological activity and enterohepatic recycling of the drug. The exclusive provision of intravenous dextrose can generate a positive feedback phenomenon by inducing greater insulin release. In refractory cases, octreotide (synthetic somatostatin) should be used in doses of 50 to 100 µg subcutaneously every 8-12 hours to directly stop insulin exocytosis mediated by calcium channels.

Drug Interactions of Clinical Relevance

• CYP2C9 inhibitors (Fluconazole, Voriconazole, Amiodarone): They substantially increase the plasma concentration of glimepiride, inducing severe hypoglycemia.
• Highly protein-binding drugs (NSAIDs, Salicylates, Warfarin): They competitively displace glimepiride from albumin, increasing the circulating free and active fraction of the sulfonylurea.
• Beta adrenergic blockers (Atenolol, Metoprolol): They mask the autonomic warning signs of hypoglycemia (tachycardia, tremor, diaphoresis), delaying the patient's taking corrective measures.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Contraindicated. It crosses the placental barrier and can cause severe and persistent neonatal hypoglycemia at birth, in addition to potential bone teratogenicity reported in preclinical models.
• Breastfeeding: Contraindicated. It is excreted in significant quantities in human breast milk, posing a risk of severe hypoglycemia in the infant.